Trials / Withdrawn
WithdrawnNCT04256148
ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Study of ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Alexion Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main objective of the study is to evaluate the safety and efficacy of ALXN1830 compared to placebo in adult participants with warm autoimmune hemolytic anemia (WAIHA).
Detailed description
This study will consist of a 4-week Screening period, 13-week Primary Treatment period, and optional Extended Treatment period (up to 2 years).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ALXN1830 | Administered via intravenous (IV) infusion |
| OTHER | Placebo | Matching placebo (sterile liquid diluent) administered via IV infusion |
Timeline
- Start date
- 2021-07-01
- Primary completion
- 2022-10-30
- Completion
- 2023-04-30
- First posted
- 2020-02-05
- Last updated
- 2020-07-13
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04256148. Inclusion in this directory is not an endorsement.